MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/1352458511421920

Медицинская библиотека · Multiple sclerosis (Houndmills, Basingstoke, England) · 2011

Statin therapy and multiple sclerosis disability in a population-based cohort.

Paz Soldán M Mateo, Pittock Sean J, Weigand Stephen D, Yawn Barbara P, Rodriguez Moses

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Axonal damage and inflammatory demyelination both occur in multiple sclerosis (MS). Some studies suggest that statins, through pleiotropic effects, reduce inflammatory episodes and protect neurons. However, other studies suggest statins have disparate impacts on these pathologic processes.

OBJECTIVE

The objective of this study was to assess disability progression in MS patients receiving statin therapy.

METHODS

We performed a retrospective medical record review of an established population-based MS prevalence cohort in Olmsted County, Minnesota, comparing disability progression between patients receiving statins and controls.

RESULTS

Duration of statin use ranged from 1.9 to 20.3 years with a mean and standard deviation of 6.8 ± 4 years. Years between assessments ranged from 0.6 to 8.2 (75% of patients having intervals >6.4 years). The median (interquartile range) absolute change of disability among the statin group was 0 (0 to +1), compared with +0.5 (0, +1) in the no-statin group. Distributions were not significantly different (p = 0.39). The mean (standard deviation) absolute change of disability scores among the statin group was +0.69 (+1.49), not significantly different from +0.61 (+1.31) in the no-statin group. Likewise, annualized disability scores did not differ significantly (p = 0.23). Eighteen (40%) patients worsened by 1.0 or more on Expanded Disability Status Scale (EDSS) in the statin group and 36 (40%) in the no-statin group (p = 0.85, chi-squared test).

CONCLUSIONS

In this cohort, disability progression did not differ between those receiving statin therapy and controls. These findings support the hypothesis that statins, in doses currently prescribed for hyperlipidemia, do not affect the long-term course of MS.

Для цитирования: Paz Soldán M Mateo, Pittock Sean J, Weigand Stephen D, Yawn Barbara P, Rodriguez Moses. Statin therapy and multiple sclerosis disability in a population-based cohort.. Multiple sclerosis (Houndmills, Basingstoke, England). 2011. DOI: 10.1177/1352458511421920.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.